

Evoke Neuroscience to Present at ROTH Capital Conference

Evoke Neuroscience has been selected to present its eVox® System, the FDA-cleared device that aids in diagnosis of memory loss, at ROTH Capital Conference.

NEW YORK, NY, USA, March 15, 2019 /EINPresswire.com/ -- [Evoke Neuroscience](#) announces it has been selected to present to the attendees of this year's ROTH Capital Conference on March 18 in Orange County, California.


Evoke will present its [eVox® System](#), the FDA-cleared device that aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, investors, and healthcare industry professionals.

Evoke has been recognized for its work to accelerate the eradication of Alzheimer's disease and other dementias. The eVox System offers doctors the opportunity to implement early interventions to reduce risk of cognitive impairment, Alzheimer's, and other dementias by aiding doctors in diagnosis of memory loss and other cognitive disorders.

Marinela Gombosov, Chief Executive Officer at Evoke Neuroscience stated, "The eVox System performs a quick, low-cost, and reimbursable procedure to measure brain health and aid in

diagnosis. This means an objective evaluation of brain function – once the exclusive domain of a neurologist – is possible in a primary care setting." And, she explains, "Our technology has the potential to change the standard of care from a cognitive questionnaire to a rapid, objective measurement of brain function – much like a blood pressure cuff is used to measure the heart."


Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand the cause of memory loss, it is important to measure key biomarkers of the brain itself. Primary and specialty care



The eVox System aids in diagnosis of cognitive disorders

physicians can use eVox to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox System is appropriate to aid in diagnosis.

Evoke boasts an impressive portfolio, including an FDA cleared diagnostic device, a Veterans Health Administration FSS contract, well-established insurance reimbursement coding (5 CPT codes), a recently renewed Premier Group Purchase Organization contract, 12 patents awarded (9 Utility, 3 Design), delivery of over 400 eVox Systems to market, and ownership of nearly 50,000 patient brain scans to be used for training AI models.



eVox measures objective and stable brain-based biomarkers

Marinela Gombosov will present on behalf of Evoke Neuroscience at the ROTH Capital Conference on: Mon, Mar 18 at 9:20-9:40 AM

About ROTH Capital Conference

The 31st ROTH Conference is scheduled for March 17-19, 2019 at the Ritz Carlton, Laguna Niguel, in Orange County, CA. With close to 550 participating companies and over 4,700 attendees, the conference will feature presentations from public and private companies in a variety of sectors. Hosted by ROTH Capital Partners, an investment banking firm dedicated to the small-cap public market, the ROTH Conference has been ranked in the top 100 events in the U.S. for 5 consecutive years.

About Evoke Neuroscience

Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful, and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.

Morgan Ingemanson
Evoke Neuroscience
9172616096
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.